A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Recruiting at 246 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Genentech, Inc.
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Research Team
DS
Donald Strickland, M.D.
Principal Investigator
Genentech, Inc.
Eligibility Criteria
Inclusion Criteria
Signed Informed Consent Form
Histologically or cytologically confirmed NSCLC
Advanced NSCLC or recurrent disease
See 3 more
Treatment Details
Interventions
- Bevacizumab (Monoclonal Antibodies)
- Erlotinib HCl (Tyrosine Kinase Inhibitor)
- Placebo (Chemotherapy)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment2 Interventions
Group II: 2Placebo Group2 Interventions
Bevacizumab is already approved in Japan, Canada for the following indications:
Approved in Japan as Avastin for:
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
Approved in Canada as Avastin for:
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genentech, Inc.
Lead Sponsor
Trials
1,578
Recruited
569,000+
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD